Bristol Myers Squibb obtained two US Food and Drug Administration approvals during the week of 7 April for combination therapy with its immuno-oncology stalwarts Opdivo (nivolumab) and Yervoy (ipilimumab) in liver and colorectal cancer settings, which should help the biopharma vie against strong competition in the IO space.
Key Takeaways
- Bristol’s Opdivo + Yervoy combo obtains FDA okays for colorectal and liver cancer settings.
The new approvals brought the combination regimen’s list of indications to nine, according to BMS. Opdivo as monotherapy or in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?